Background/aim: High-dose melphalan and autologous hematopoietic stem cell transplantation (AHSCT) is the standard treatment strategy for multiple myeloma (MM) patients who are eligible for it. The recommended dose of CD34+ hematopoietic progenitor cells (HPCs) for adequate engraftment is above 2 × 106/kg. The aim of this study was to evaluate the relationship between the dose of CD34+HPCs and survival in MM patients who underwent AHSCT at a tertiary care center. Materials and methods: Enrolled in this study were 271 MM patients who underwent AHSCT between 2003 and 2019. Clinical characteristics of the patients, disease status pre-AHSCT, reinfused CD34+ cell doses, and neutrophil and platelet engraftment days were recorded, retrospectively. The patients were divided into 2 groups according to whether the dose of reinfused CD 34+ HPCs was <5 × 106/kg or ≥5 × 106/kg. The groups were compared in terms of engraftment and overall survival (OS) times. Results: The median age of the patients was 54.8 (33–76) years. The median dose of infused CD34+ HPCs was 5.94 × 106/kg (1.47–59.5 × 106/kg). The median follow-up period was 54 months (4–211). The median OS of the patients was 103 months (11–144). The median neutrophil and platelet engraftment time was 10 (8–24) and 11 (7–40) days. Doses of <5 × 106/kg and ≥5 × 106/kg CD34+ HPC were reinfused in 38.1% and 61.9% of the patients, respectively. There was a negative significant correlation between the reinfused CD34+cell level and neutrophil/platelet engraftment times (r = –0.32, P < 0.001; r = –0.27, P < 0.001, respectively). The median OS times were observed as 103 months (11–144) and 145 months (123–166) for patients who had been administered <5 × 106/kg and ≥5 × 106/kg of CD34+ HPCs, respectively (P = 0.009). Conclusion: The increased amount of CD34+ autologous hematopoietic stem cell dose after high dose melphalan chemotherapy in MM patients shortened the platelet and neutrophil engraftment time and increased OS. Early platelet engraftment and administration of a CD34+ HPC count that is ≥5 × 106/kg can be considered as predictors of better survival in patients. This work is licensed under a Creative Commons Attribution 4.0 International License.
Background/aim: High-dose melphalan and autologous hematopoietic stem cell transplantation (AHSCT) is the standard treatment strategy for multiple myeloma (MM) patients who are eligible for it. The recommended dose of CD34+ hematopoietic progenitor cells (HPCs) for adequate engraftment is above 2 × 106/kg. The aim of this study was to evaluate the relationship between the dose of CD34+HPCs and survival in MMpatients who underwent AHSCT at a tertiary care center. Materials and methods: Enrolled in this study were 271 MMpatients who underwent AHSCT between 2003 and 2019. Clinical characteristics of the patients, disease status pre-AHSCT, reinfused CD34+ cell doses, and neutrophil and platelet engraftment days were recorded, retrospectively. The patients were divided into 2 groups according to whether the dose of reinfused CD 34+ HPCs was <5 × 106/kg or ≥5 × 106/kg. The groups were compared in terms of engraftment and overall survival (OS) times. Results: The median age of the patients was 54.8 (33–76) years. The median dose of infused CD34+ HPCs was 5.94 × 106/kg (1.47–59.5 × 106/kg). The median follow-up period was 54 months (4–211). The median OS of the patients was 103 months (11–144). The median neutrophil and platelet engraftment time was 10 (8–24) and 11 (7–40) days. Doses of <5 × 106/kg and ≥5 × 106/kg CD34+ HPC were reinfused in 38.1% and 61.9% of the patients, respectively. There was a negative significant correlation between the reinfused CD34+cell level and neutrophil/platelet engraftment times (r = –0.32, P < 0.001; r = –0.27, P < 0.001, respectively). The median OS times were observed as 103 months (11–144) and 145 months (123–166) for patients who had been administered <5 × 106/kg and ≥5 × 106/kg of CD34+ HPCs, respectively (P = 0.009). Conclusion: The increased amount of CD34+ autologous hematopoietic stem cell dose after high dose melphalan chemotherapy in MMpatients shortened the platelet and neutrophil engraftment time and increased OS. Early platelet engraftment and administration of a CD34+ HPC count that is ≥5 × 106/kg can be considered as predictors of better survival in patients. This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors: Patrick J Stiff; Ivana Micallef; Auayporn P Nademanee; Edward A Stadtmauer; Richard T Maziarz; Brian J Bolwell; Gary Bridger; Sachin Marulkar; Frank J Hsu; John F DiPersio Journal: Biol Blood Marrow Transplant Date: 2010-11-30 Impact factor: 5.742
Authors: Patrick Wuchter; Dan Ran; Thomas Bruckner; Thomas Schmitt; Mathias Witzens-Harig; Kai Neben; Hartmut Goldschmidt; Anthony D Ho Journal: Biol Blood Marrow Transplant Date: 2009-11-17 Impact factor: 5.742
Authors: Francesco Lanza; Diana C Campioni; Andrzej Hellmann; Giuseppe Milone; Anders Wahlin; Jan Walewski; Pierangelo Spedini; Cristina Fiamenghi; Antonio Cuneo; Wanda Knopińska; Monica Swierkowska-Czeneszew; Jordi Petriz; Stefan Fruehauf; Dominique Farge; Mohamad Mohty; Jacob Passweg; Tapani Ruuto; Alejandro Madrigal; Hans E Johnsen Journal: Biol Blood Marrow Transplant Date: 2013-08-27 Impact factor: 5.742
Authors: José Luis García de Veas Silva; Carmen Bermudo Guitarte; Paloma Menéndez Valladares; Johanna Carolina Rojas Noboa; Krysta Kestler; Rafael Duro Millán Journal: PLoS One Date: 2016-11-28 Impact factor: 3.240
Authors: Neerja Kushwaha; Sudeep Kumar; Mohd Anas Sheikh; Joseph Philip; Sanjeevan Sharma; Amit Kumar Biswas; Rajneesh Kumar Joshi Journal: Med J Armed Forces India Date: 2021-03-24